Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

NCT06237296

CompletedPhase 1

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions: Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection

Interventions: RSV/hMPV mRNA LNP 1, RSV/hMPV mRNA LNP 2, RSV mRNA LNP 1, hMPV mRNA LNP 1

Countries: United States, Australia

The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older. Treatment: * RSV/hMPV mRNA / LNP 1 at 3-4 different doses or, * RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or, * RSV mRNA / LNP 1 at 1 dose or, * hMPV mRNA / LNP 1 at 1 dose

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

-Informed consent form (ICF) has been signed and dated

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

-Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.

--The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Locations (17)
  • Gardena, California, United States
  • Hallandale, Florida, United States
  • Meridian, Idaho, United States
  • Sioux City, Iowa, United States
  • New Orleans, Louisiana, United States
  • Binghamton, New York, United States
  • Cleveland, Ohio, United States
  • North Charleston, South Carolina, United States
  • Charlottesville, Virginia, United States
  • Blacktown, New South Wales, Australia
  • Botany, New South Wales, Australia
  • Kanwal, New South Wales, Australia
  • Sydney, New South Wales, Australia
  • Herston, Queensland, Australia
  • Morayfield, Queensland, Australia
  • Camberwell, Victoria, Australia
  • Canberra, Australia